161 related articles for article (PubMed ID: 26978241)
1. The budget impact of cervical cancer screening using HPV primary screening.
Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT
Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241
[TBL] [Abstract][Full Text] [Related]
2. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
Vijayaraghavan A; Efrusy MB; Goodman KA; Santas CC; Huh WK
Gynecol Oncol; 2010 Nov; 119(2):237-42. PubMed ID: 20713299
[TBL] [Abstract][Full Text] [Related]
5. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
6. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.
Termrungruanglert W; Khemapech N; Tantitamit T; Havanond P
J Gynecol Oncol; 2019 Mar; 30(2):e17. PubMed ID: 30740950
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation and budget impact analysis of cervical cancer screening using cobas 4800 HPV screening technology in the public sector of South Africa.
Dreyer G; Maske C; Stander M
PLoS One; 2019; 14(9):e0221495. PubMed ID: 31509545
[TBL] [Abstract][Full Text] [Related]
9. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
Kim JJ; Ortendahl J; Goldie SJ
Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of strategies for cervical cancer prevention in India.
Chauhan AS; Prinja S; Srinivasan R; Rai B; Malliga JS; Jyani G; Gupta N; Ghoshal S
PLoS One; 2020; 15(9):e0238291. PubMed ID: 32870941
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of primary cytology and HPV DNA cervical screening.
Bistoletti P; Sennfält K; Dillner J
Int J Cancer; 2008 Jan; 122(2):372-6. PubMed ID: 17935124
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
[TBL] [Abstract][Full Text] [Related]
17. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
Burger EA; Ortendahl JD; Sy S; Kristiansen IS; Kim JJ
Br J Cancer; 2012 Apr; 106(9):1571-8. PubMed ID: 22441643
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility and budget impact analyses of cervical cancer screening using self-collected samples for HPV DNA testing in Thailand.
Kositamongkol C; Kanchanasurakit S; Mepramoon E; Talungchit P; Chaopotong P; Kengkla K; Chaisathaphol T; Saokaew S; Phisalprapa P
BMC Public Health; 2023 Dec; 23(1):2413. PubMed ID: 38049773
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of HPV DNA test as primary screening method for cervical cancer: A health policy discussion in Greece.
Skroumpelos A; Agorastos T; Constantinidis T; Chatzistamatiou K; Kyriopoulos J
PLoS One; 2019; 14(12):e0226335. PubMed ID: 31830114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
